Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03278028 · ClinicalTrials.gov registry record · Phase 2
A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
A Phase 2 study of Common Wart, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
- 16
- Study locations
NCT03278028: Completed Phase 2 study of Common Wart, sponsored by Aclaris Therapeutics.
NCT03278028 is a Phase 2 study of Common Wart that has completed, run by Aclaris Therapeutics. The registered enrollment target is 159 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03278028, a Phase 2 study of Common Wart, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
- 16
- Study locations
Study Summary
The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.
Primary Outcome
Physician's Wart Assessment Grade Descriptor 0 Clear: No visible wart. No further treatment is indicated. 1. Near Clear: A visible wart that is less than 3 mm in maximal diameter (or length) 2. A visible wart ≥ 3 mm and \< 6 mm in maximal diameter (or length) 3. A visible wart ≥ 6 mm in maximal diameter (or length)
Conditions Studied
Interventions
- DRUG A-101 Topical Solution
- DRUG A-101 Vehicle Solution
Study Locations (16)
California
- Aclaris Investigational Site - Encinitas
- Aclaris Investigational Site - Los Angeles
Tennessee
- Aclaris Investigational Site - Knoxville
- Aclaris Investigational Site - Nashville
Texas
- Aclaris Investigational Site - College Station
- Aclaris Investigational Site - Houston
Virginia
- Aclaris Investigational Site - Lynchburg
- Aclaris Investigational Site - Norfolk
Arizona
- Aclaris Investigational Site - Glendale
Arkansas
- Aclaris Investigational Site - Fort Smith
Colorado
- Aclaris Investigational Site - Denver
Nebraska
- Aclaris Investigational Site - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2017-07-13 |
| Est. Completion | 2018-03-01 |
| Phase | Phase 2 |
What the finished NCT03278028 record still lists
NCT03278028 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher).
The record links to 1 condition, with Common Wart appearing as the primary indexed condition, and to 2 interventions - of which A-101 Topical Solution is the first listed.
NCT03278028 lists 16 locations in 12 states (California, Tennessee, Texas).
Frequently Asked Questions
What is clinical trial NCT03278028 about?
NCT03278028 is a clinical study titled "A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts". The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.
What is the current status of trial NCT03278028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2017-07-13. Estimated completion is 2018-03-01.
What conditions does trial NCT03278028 study?
This clinical trial studies the following conditions: Common Wart.
What interventions are being tested in trial NCT03278028?
The interventions under investigation include: A-101 Topical Solution (DRUG), A-101 Vehicle Solution (DRUG).
Who is sponsoring clinical trial NCT03278028?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03278028 being conducted?
This trial has 16 study locations across Arizona, Arkansas, California, Colorado, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Common Wart
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03278028's enrollment target sits among peer trials
159 442nd of 2000 higher than 1,558 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI